MAM
MYGN icon

Meeder Asset Management’s Myriad Genetics MYGN Stock Holding History

Meeder Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,922
Closed -$135K – 979
2024
Q3 		$135K Buy
4,922
+4,207
+588% +$114K 0.01% 260
2024
Q2 		$17.5K Buy
+715
New +$15.7K ﹤0.01% 546
2023
Q1 		– Sell
-843
Closed -$12.2K – 761
2022
Q4 		$12.2K Buy
843
+726
+621% +$13.5K ﹤0.01% 635
2022
Q3 		$2K Buy
117
+73
+166% +$1.68K ﹤0.01% 1832
2022
Q2 		$1K Buy
44
+1
+2% +$21 ﹤0.01% 2036
2022
Q1 		$1K Buy
+43
New +$1.1K ﹤0.01% 2215
2021
Q4 		– Sell
-3,681
Closed -$118K – 1911
2021
Q3 		$118K Buy
3,681
+3,144
+585% +$104K 0.01% 857
2021
Q2 		$16K Sell
537
-242
-31% -$6.99K ﹤0.01% 1536
2021
Q1 		$23K Buy
779
+737
+1,755% +$20.9K ﹤0.01% 1363
2020
Q4 		$1K Sell
42
-3,518
-99% -$56.8K ﹤0.01% 1697
2020
Q3 		$46K Sell
3,560
-555
-13% -$7.02K ﹤0.01% 972
2020
Q2 		$47K Buy
+4,115
New +$58.4K ﹤0.01% 935
2020
Q1 		– Sell
-1,041
Closed -$28K – 2453
2019
Q4 		$28K Sell
1,041
-762
-42% -$21K ﹤0.01% 1237
2019
Q3 		$52K Buy
+1,803
New +$52.5K ﹤0.01% 1007
2019
Q2 		– Sell
-34
Closed -$1K – 2101
2019
Q1 		$1K Sell
34
-1,237
-97% -$37.7K ﹤0.01% 1631
2018
Q4 		$37K Sell
1,271
-5,061
-80% -$182K ﹤0.01% 890
2018
Q3 		$290K Sell
6,332
-561
-8% -$24.9K 0.02% 445
2018
Q2 		$258K Buy
6,893
+3,674
+114% +$124K 0.02% 470
2018
Q1 		$95K Sell
3,219
-1,991
-38% -$67.4K 0.01% 555
2017
Q4 		$179K Buy
5,210
+1,918
+58% +$64.7K 0.02% 474
2017
Q3 		$119K Buy
3,292
+3,010
+1,067% +$85.9K 0.01% 539
2017
Q2 		$7K Buy
282
+2
+0.7% +$42 ﹤0.01% 1095
2017
Q1 		$5K Buy
280
+169
+152% +$3K ﹤0.01% 1079
2016
Q4 		$2K Buy
+111
New +$2.01K ﹤0.01% 934

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Meeder Asset Management's MYGN Position: Q4 2024 in Review

Meeder Asset Management sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 4,922 shares — an estimated $135K sold.

Meeder Asset Management first reported a position in MYGN in Q4 2016 and held it in 24 quarters. The position peaked at $290K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Meeder Asset Management reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 4,922 Myriad Genetics shares in Q4 2024, an estimated $135K.
  • Meeder Asset Management first reported a position in Myriad Genetics in Q4 2016 and held it in 24 quarters.
  • Meeder Asset Management's Myriad Genetics position peaked at $290K in Q3 2018.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.